Cellectis (CLLS) Other financing activities (2020 - 2023)
Cellectis (CLLS) posted quarterly Other financing activities of $1.3 million for Q2 2023, up 417.16% year-over-year from $246536.8 in Q2 2022, and up 151.98% quarter-over-quarter from $506000.0 in Q1 2023.
Cellectis (CLLS) Other financing activities (2020 - 2023) Analysis & Trends
Cellectis' Other financing activities history runs 4 years deep, the most recent figure standing at $1.3 million for Q2 2023.
- In Q2 2023, Other financing activities rose 417.16% year-over-year to $1.3 million; the TTM figure through Sep 2023 stood at $478000.0 (down 94.58% YoY), while the FY2015 annual figure was $349.1 million, up 133.73% from the prior year.
- Other financing activities for Q2 2023 stood at $1.3 million, up from $506000.0 in the prior quarter.
- The five-year high for Other financing activities was $11.8 million in Q1 2021, with the low at -$1.3 million in Q3 2022.
- The 4-year median for Other financing activities is $269000.0 (2020), against an average of $2.8 million.
- The sharpest annual moves came in 2022 and 2023: Other financing activities tumbled 1397.7% in 2022, then jumped 417.16% in 2023.
- Cellectis' Other financing activities stood at $32000.0 in 2020, then slumped by 371.88% to -$87000.0 in 2021, then sank by 1397.7% to -$1.3 million in 2022, then jumped by 197.85% to $1.3 million in 2023.
- Business Quant data shows CLLS's Other financing activities at $1.3 million in Q2 2023, $506000.0 in Q1 2023, and -$1.3 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.28 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 506,000.00 |
| Mar 31, 2023 | 506,000.00 |
| Sep 30, 2022 | -1.30 Mn |
| Sep 30, 2022 | -1.30 Mn |
| Jun 30, 2022 | -402,000.00 |
| Jun 30, 2022 | -402,000.00 |
| Mar 31, 2022 | 10.61 Mn |
| Mar 31, 2022 | 10.61 Mn |
| Sep 30, 2021 | -87,000.00 |
| Sep 30, 2021 | -87,000.00 |
| Mar 31, 2021 | 11.82 Mn |
| Mar 31, 2021 | 11.82 Mn |
| Sep 30, 2020 | 32,000.00 |
| Sep 30, 2020 | 32,000.00 |